TB drug development: Immunology at the table

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 308-318

  Nathan, Carl ^a   Barry, Clifton E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Drug resistance; Immunopathology; Non replication; Persistence; Phenotypic tolerance; Viable but non culturable

Indexed keywords

ACYLTRANSFERASE; ANTIBIOTIC AGENT; GELATINASE B; HOST FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; ISONIAZID; NITRITE; NITROGEN; PENICILLIN DERIVATIVE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACIDIFICATION; ARTICLE; BACTERICIDAL ACTIVITY; BRONCHUS MUCOSA; CARBON SOURCE; DRUG DEVELOPMENT; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOPATHOLOGY; LUNG; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84923165718     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12275     Document Type: Article

References (68)

1. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 2014;12:159-167.
2. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet 2011;50:689-704.
3. Via LE, et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 2013;81:2909-2919.
4. Lin PL, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014;20:75-79.
5. Subbian S, et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011;7:e1002262.
6. Mayer-Barber KD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014;511:99-103.
7. Tobin DM, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012;148:434-446.
8. Tobin DM, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010;140:717-730.
9. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci Transl Med 2011;3:71ps76.
10. Walsh C. Where will new antibiotics come from? Nat Rev Microbiol 2003;1:65-70.
11. Devadatta S, et al. Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organization 1961;25:807-829.
12. Andries K, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE 2014;9:e102135.
13. Nathan C. Fresh approaches to anti-infective therapies. Sci Transl Med 2012;4:140sr142.
14. Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 1944;497-500.
15. Maisonneuve E, Gerdes K. Molecular mechanisms underlying bacterial persisters. Cell 2014;157:539-548.
16. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science 2004;305:1622-1625.
17. Wakamoto Y, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 2013;339:91-95.
18. Amato SM, Orman MA, Brynildsen MP. Metabolic control of persister formation in Escherichia coli. Mol Cell 2013;50:475-487.
19. Orman MA, Brynildsen MP. Dormancy is not necessary or sufficient for bacterial persistence. Antimicrob Agents Chemother 2013;57:3230-3239.
20. Schnappinger D, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 2003;198:693-704.
21. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009;323:1215-1218.
22. Vilcheze C, et al. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother 2011;55:3889-3898.
23. Phillips PP, Nunn AJ, Paton NI. Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? Int J Tuber Lung Dis 2013;17:807-809.
24. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med 2010;181:174-180.
25. Oliver JD. Recent findings on the viable but nonculturable state in pathogenic bacteria. FEMS Microbiol Rev 2010;34:415-425.
26. Scanga CA, et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999;67:4531-4538.
27. Bryk R, et al. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 2008;3:137-145.
28. Gold B, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci USA 2012;109:16004-16011.
29. Gill WP, et al. A replication clock for Mycobacterium tuberculosis. Nat Med 2009;15:211-214.
30. de Carvalho LP, Lin G, Jiang X, Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J Medicinal Chem 2009;52:5789-5792.
31. Zheng P, et al. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. J Medicinal chem 2014;57:3755-3772.
32. Johnson PJ, Levin BR. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet 2013;9:e1003123.
33. Dorr T, Lewis K, Vulic M. SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet 2009;5:e1000760.
34. Deris JB, et al. The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria. Science 2013;342:1237435.
35. Nandakumar M, Nathan C, Rhee KY. Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. Nat Commun 2014;5:4306.
36. Dartois V, Barry CE 3rd. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 2013;23:4741-4750.
37. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43:717-731.
38. Dahl JL, et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003;100:10026-10031.
39. Song T, et al. Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the beta' subunit of RNA polymerase. Mol Microbiol 2014;91:1106-1119.
40. Sala C, et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010;54:4150-4158.
41. Bloch H, Segal W. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol 1956;72:132-141.
42. McKinney JD, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-738.
43. Eoh H, Rhee KY. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2013;110:6554-6559.
44. Eoh H, Rhee KY. Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of Mycobacterium tuberculosis on fatty acids. Proc Natl Acad Sci USA 2014;111:4976-4981.
45. Marrero J, Trujillo C, Rhee KY, Ehrt S. Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog 2013;9:e1003116.
46. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 2008;105:4376-4380.
47. Trujillo C, et al. Triosephosphate isomerase is dispensable in vitro yet essential for Mycobacterium tuberculosis to establish infection. MBio 2014;5:e00085.
48. Puckett S, et al. Inactivation of fructose-1, 6-bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PLoS Pathog 2014;10:e1004144.
49. Beste DJ, et al. (1)(3)C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation. PLoS Pathog 2011;7:e1002091.
50. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003;302:654-659.
51. Watanabe S, et al. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog 2011;7:e1002287.
52. Via LE, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008;76:2333-2340.
53. Cunningham-Bussel A, Zhang T, Nathan CF. Nitrite produced by Mycobacterium tuberculosis in human macrophages in physiologic oxygen impacts bacterial ATP consumption and gene expression. Proc Natl Acad Sci USA 2013;110:E4256-E4265.
54. Lundberg JO, Weitzberg E, Cole JA, Benjamin N. Nitrate, bacteria and human health. Nat Rev Microbiol 2004;2:593-602.
55. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
56. Andersson J, Samarina A, Fink J, Rahman S, Grundstrom S. Impaired expression of perforin and granulysin in CD8+ T cells at the site of infection in human chronic pulmonary tuberculosis. Infect Immun 2007;75:5210-5222.
57. Choi HS, Rai PR, Chu HW, Cool C, Chan ED. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med 2002;166:178-186.
58. Facchetti F, et al. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am J Pathol 1999;154:145-152.
59. Nathan C. Inducible nitric oxide synthase in the tuberculous human lung. Am J Respir Crit Care Med 2002;166:130-131.
60. Nicholson S, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996;183:2293-2302.
61. Rahman S, et al. Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory t cells in the granulomatous lesions. Am J Pathol 2009;174:2211-2224.
62. Schon T, et al. Local production of nitric oxide in patients with tuberculosis. Int J Tuber Lung Dis 2004;8:1134-1137.
63. Vogt G, Nathan C. In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J Clin Invest 2011;121:3889-3901.
64. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014;41:21-35.
65. Franzblau SG, et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 2012;92:453-488.
66. Pan H, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005;434:767-772.
67. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995;63:736-740.
68. MacMicking JD, et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997;94:5243-5248.